{"id":"deoxycholic-acid","rwe":[{"pmid":"41905832","year":"2026","title":"Yinchenhao decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.","finding":"","journal":"Journal of integrative medicine","studyType":"Clinical Study"},{"pmid":"41901254","year":"2026","title":"Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.","finding":"","journal":"Pharmaceuticals (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41898511","year":"2026","title":"Bile Acid Metabolism Affects Muscle Regeneration in Aging Skeletal Muscle in a Manner Associated with Regulation of ABCB1 Expression.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41895615","year":"2026","title":"Altered serum 3β-hydroxy bile acids in major depressive disorder and associations with symptom dimensions.","finding":"","journal":"Journal of affective disorders","studyType":"Clinical Study"},{"pmid":"41880860","year":"2026","title":"Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.","finding":"","journal":"EBioMedicine","studyType":"Clinical Study"}],"_fda":{"id":"c67c4873-6322-42dc-8a2b-da3a7012a435","set_id":"fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553","openfda":{"nui":["N0000191548","N0000008476"],"unii":["005990WHZZ"],"route":["SUBCUTANEOUS"],"rxcui":["1649975","1649980"],"spl_id":["c67c4873-6322-42dc-8a2b-da3a7012a435"],"brand_name":["KYBELLA"],"spl_set_id":["fe431ed4-ea6f-4e99-b4bc-ec25ae7b8553"],"package_ndc":["61168-101-01","61168-101-04","61168-101-91","61168-101-94","61168-101-03"],"product_ndc":["61168-101"],"generic_name":["DEOXYCHOLIC ACID"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Decreased Cell Membrane Integrity [PE]"],"substance_name":["DEOXYCHOLIC ACID"],"pharm_class_epc":["Cytolytic Agent [EPC]"],"manufacturer_name":["Kythera Biopharmaceuticals Inc."],"application_number":["NDA206333"],"is_original_packager":[true]},"version":"25","pregnancy":["8 . 1 Preg n a n c y Risk Summary There are no adequate and well-controlled studies of KYBELLA injection in pregnant women to inform the drug-associated risk. In animal reproduction studies, no fetal harm was observed with the subcutaneous administration of deoxycholic acid to rats during organogenesis at doses up to 5 times the maximum recommended human dose (MRHD) of 100 mg [see Data] . The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk of major birth defects in the U.S. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. Data Animal Data Embryofetal development studies have been performed in rats and rabbits using subcutaneous doses of deoxycholic acid administered during the period of organogenesis. For the basis of comparing animal to human doses, the MRHD is 1.7 mg/kg (100 mg/60 kg). No evidence of fetal harm was observed in rats at up to the highest dose tested (50 mg/kg) which is 5-fold higher than the MRHD of KYBELLA based on a mg/m 2 comparison. However, missing intermediate lung lobe was noted in rabbits at all dose levels tested including the lowest dose (10 mg/kg) which is 2-fold higher than the MRHD of KYBELLA based on a mg/m 2 comparison. These effects may be related to maternal toxicity, which was also seen at all dose levels tested."],"description":["11 DESCRIPTION KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear colorless, sterile solution for subcutaneous use. It contains a cytolytic agent, deoxycholic acid, as the active ingredient. The chemical name of deoxycholic acid is 3α,12α-dihydroxy-5β-cholan-24-oic acid, and its molecular formula is C 24 H 40 O 4 , and its molecular weight is 392.57 g/mol. The chemical structure of deoxycholic acid is: Each 2 mL vial of KYBELLA injection contains 20 mg synthetic deoxycholic acid as the active ingredient and the following inactive ingredients: benzyl alcohol (18 mg), dibasic sodium phosphate (2.84 mg), sodium chloride (8.76 mg), sodium hydroxide (2.86 mg) in water for injection, USP. Hydrochloric acid and additional sodium hydroxide are added as necessary to adjust the formulation to pH 8.3. Each vial is for single patient use. The chemical structure of deoxycholic acid."],"how_supplied":["1 6 HOW SUPPLIED/STORAGE AND HANDLING KYBELLA (deoxycholic acid) injection, 10 mg/mL is a clear, colorless, sterile solution supplied in 2 mL, single patient use vials in the following dispensing pack: 4 vials, NDC 61168-101-04 Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C to 30°C (59°F to 86°F) [See USP Controlled Room Temperature]. KYBELLA has a unique hologram on the vial label. If you do not see a hologram, do not use the product and call 1-800-678-1605. Each vial is for a single patient use. Do not dilute or mix KYBELLA with other compounds. Discard unused portion."],"geriatric_use":["8.5 Geriatric Use The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"pediatric_use":["8 . 4 Ped i atr i c Use Safety and effectiveness in patients below the age of 18 years have not been established and KYBELLA is not intended for use in children or adolescents."],"effective_time":"20241030","clinical_studies":["14 CLINICAL STUDIES Two randomized, multi-center, double-blind, placebo-controlled trials of identical design were conducted to evaluate KYBELLA injection for use in improvement in the appearance of convexity or fullness associated with submental fat. The trials enrolled healthy adults (ages 19 to 65, BMI ≤ 40 kg/m 2 ) with moderate or severe convexity or fullness associated with submental fat (i.e., grade 2 or 3 on 5-point grading scales, where 0 = none and 4 = extreme), as judged by both clinician and subject ratings. Subjects received up to 6 treatments with KYBELLA (N=514, combined trials) or placebo (N=508, combined trials) at no less than 1 month intervals. Use of ice/cold packs, topical and/or injectable local anesthesia was allowed during the clinical trials. Injection volume was 0.2 mL per injection site, spaced 1 cm apart into the submental fat tissue, which is also expressed in dose per area as 2 mg/cm 2 . For each treatment session a maximum of 100 mg (10 mL) was permitted over the entire treatment area. Subjects were administered an average of 6.4 mL at the first treatment session, and subjects who received all six treatments were administered an average of 4.4 mL at the sixth treatment session. Fifty-nine percent of subjects received all six treatments. In these trials, the mean age was 49 years and the mean BMI was 29 kg/m 2 . Most of the subjects were women (85%) and Caucasian (87%). At baseline, 51% of the subjects had a clinician-rated submental fat severity rating of moderate and 49% had a severe submental fat rating. The co-primary efficacy assessments were based on at least 2-grade and at least 1-grade improvements in submental convexity or fullness on the composite of clinician-reported and patient-reported ratings of submental fat 12 weeks after final treatment. Additionally, changes in submental fat volume were evaluated in a subset of subjects (N=449, combined trials) using magnetic resonance imaging (MRI). Visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were also evaluated using a 6-question survey, with each question rated from 0 (not at all) to 10 (extremely/very much). Reductions in submental fat volume were observed more frequently in the KYBELLA group compared to the placebo group as measured by the composite clinician and patient ratings ( Table 2 ). The composite response rates by visit are presented in Figure 4 . Table 2. ≥ 2-Grade and ≥ 1-Grade Composite Clinician and Patient Response 12 Weeks After Final Treatment Trial 1 Trial 2 Endpoint KYBELLA (N=256) Placebo (N=250) KYBELLA (N=258) Placebo (N=258) 2-Grade Composite Response a 13.4% <0.1% 18.6% 3.0% 1-Grade Composite Response b 70.0% 18.6% 66.5% 22.2% a At least 2 grade reduction on both the clinician-reported and patient-reported ratings of submental fat b At least 1 grade reduction on both the clinician-reported and patient-reported ratings of submental fat Figure 4 . ≥ 2 -Grade and ≥ 1 -Grade Composite Clinician and Patient Response Note: Subjects were followed up 4, 12 and 24 weeks after the last treatment. Forty-one percent of subjects received fewer than 6 treatments and entered the post-treatment period earlier than Week 24. A greater proportion of KYBELLA-treated subjects had at least a 10% reduction in submental fat volume as compared to placebo-treated subjects when evaluated by MRI (43% vs 5%, respectively). The overall patient-reported satisfaction and self-perceived visual attributes showed greater improvement in the KYBELLA group than in the placebo group. Figure 5. ≥ 2-Grade and ≥ 1-Grade Composite Clinician and Patient Response"],"pharmacodynamics":["1 2 .2 Phar m a c o d y n a mics Cardiac Electrophysiology At therapeutic doses, KYBELLA does not prolong the QTc interval."],"pharmacokinetics":["1 2 .3 Phar m a c o k in et i cs Endogenous deoxycholic acid plasma levels are highly variable within and between individuals; most of this natural bile component is sequestered in the enterohepatic circulation loop. Absorption and Distribution Deoxycholic acid from KYBELLA is rapidly absorbed following subcutaneous injection. After dosing with the maximum recommended single treatment dose with KYBELLA (100 mg), maximum plasma concentrations (mean C max ) were observed with a median T max of 18 minutes after injection. The mean (±SD) C max value was 1024 ± 304 ng/mL and was 3.2-fold higher than average C max values observed during a 24-hour baseline endogenous period in the absence of KYBELLA. After maximum recommended single treatment dose (100 mg), mean (±SD) deoxycholic acid exposure (AUC 0-24 ) was 7896 ± 2269 ng.hr/mL and was 1.6-fold higher over endogenous exposure. Post-treatment deoxycholic acid plasma levels returned to the endogenous range within 24 hours. No accumulation is expected with the proposed treatment frequency. Deoxycholic acid is extensively bound to proteins in plasma (98%). Metabolism and Excretion Endogenous deoxycholic acid is a product of cholesterol metabolism and is excreted intact in feces. Deoxycholic acid is not metabolized to any significant extent under normal conditions. Deoxycholic acid from KYBELLA joins the endogenous bile acid pool in the enterohepatic circulation and is excreted along with the endogenous deoxycholic acid. In Vitro Assessment of Drug Interactions Results from in vitro studies indicate that deoxycholic acid does not inhibit or induce human cytochrome P450 (CYP) enzymes at clinically relevant concentrations. Deoxycholic acid does not inhibit the following transporters: P-gp, BCRP, MRP4, MRP2, OATP1B1, OATP2B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, NTCP, and ASBT. Specific Populations Hepatic Impairment KYBELLA has not been studied in subjects with hepatic impairment. Considering the intermittent dose frequency, the small dose administered that represents approximately 3% of the total bile acid pool, and the highly variable endogenous deoxycholic acid levels, the pharmacokinetics of deoxycholic acid following KYBELLA injection is unlikely to be influenced by hepatic impairment. Pharmacokinetic E ffects of Gender Deoxycholic acid pharmacokinetics were not influenced by gender."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions (>20% of subjects) include injection site edema/swelling, hematoma, pain, numbness, erythema and induration. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6 . 1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In two double-blind, placebo-controlled clinical trials 513 subjects were treated with KYBELLA injection and 506 subjects were treated with placebo. The population was 19-65 years old, 85% were women, 87% Caucasian, 8% African American. At baseline the population had a mean BMI of 29 kg/m 2 , moderate to severe submental convexity (graded as 2 or 3 on a 0 to 4 scale) and without excessive skin laxity. Subjects received up to 6 treatments at least 1 month apart and were followed for up to 6 months after the last received treatment. The most commonly reported adverse reactions are listed below ( Table 1 ). Table 1. Adverse Reactions in the Pooled Trials 1 and 2 a Adverse reactions KYBELLA (N=513) n (%) Placebo (N=506) n (%) Injection site reactions 492 (96%) 411 (81%) edema/swelling 448 (87%) 218 (43%) hematoma/bruising 368 (72%) 353 (70%) pain 356 (70%) 160 (32%) numbness 341 (66%) 29 (6%) erythema 136 (27%) 91 (18%) induration 120 (23%) 13 (3%) paresthesia 70 (14%) 20 (4%) nodule 68 (13%) 14 (3%) pruritus 64 (12%) 30 (6%) skin tightness 24 (5%) 6 (1%) site warmth 22 (4%) 8 (2%) nerve injury b 20 (4 %) 1 (<1%) Headache 41 (8%) 20 (4%) Oropharyngeal pain 15 (3%) 7 (1%) Hypertension 13 (3%) 7 (1%) Nausea 12 (2%) 3 (1%) Dysphagia 10 (2%) 1 (<1%) a Adverse reactions that occurred in ≥ 2% KYBELLA treated subjects and at greater incidence than placebo b Marginal mandibular nerve paresis Other adverse reactions associated with the use of KYBELLA include: injection site hemorrhage, injection site discoloration, pre-syncope/syncope, lymphadenopathy, injection site urticaria, and neck pain. Adverse reactions that lasted more than 30 days and occurred in more than 10% of subjects were injection site numbness (42%), injection site edema/swelling (20%), injection site pain (16%), and injection site induration (13%). 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of KYBELLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to KYBELLA exposure. Administration site conditions : injection site ulceration, necrosis, infection, alopecia, scarring, and mass. Immune System Disorders: Hypersensitivity reactions including rash, urticaria, and itching. Nervous System Disorders: Oral hypoaesthesia and oral paraesthesia. Procedural Complications: Vascular injury due to inadvertent intravascular injection."],"contraindications":["4 CONTRAINDICATIONS KYBELLA injection is contraindicated in the presence of infection at the injection sites. KYBELLA is contraindicated: In the presence of infection at the injection sites . ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action KYBELLA injection is a cytolytic drug, which when injected into tissue physically destroys the cell membrane causing lysis."],"clinical_pharmacology":["12 CLINICAL PHARMACO L OGY 12.1 Mechanism of Action KYBELLA injection is a cytolytic drug, which when injected into tissue physically destroys the cell membrane causing lysis. 1 2 .2 Phar m a c o d y n a mics Cardiac Electrophysiology At therapeutic doses, KYBELLA does not prolong the QTc interval. 1 2 .3 Phar m a c o k in et i cs Endogenous deoxycholic acid plasma levels are highly variable within and between individuals; most of this natural bile component is sequestered in the enterohepatic circulation loop. Absorption and Distribution Deoxycholic acid from KYBELLA is rapidly absorbed following subcutaneous injection. After dosing with the maximum recommended single treatment dose with KYBELLA (100 mg), maximum plasma concentrations (mean C max ) were observed with a median T max of 18 minutes after injection. The mean (±SD) C max value was 1024 ± 304 ng/mL and was 3.2-fold higher than average C max values observed during a 24-hour baseline endogenous period in the absence of KYBELLA. After maximum recommended single treatment dose (100 mg), mean (±SD) deoxycholic acid exposure (AUC 0-24 ) was 7896 ± 2269 ng.hr/mL and was 1.6-fold higher over endogenous exposure. Post-treatment deoxycholic acid plasma levels returned to the endogenous range within 24 hours. No accumulation is expected with the proposed treatment frequency. Deoxycholic acid is extensively bound to proteins in plasma (98%). Metabolism and Excretion Endogenous deoxycholic acid is a product of cholesterol metabolism and is excreted intact in feces. Deoxycholic acid is not metabolized to any significant extent under normal conditions. Deoxycholic acid from KYBELLA joins the endogenous bile acid pool in the enterohepatic circulation and is excreted along with the endogenous deoxycholic acid. In Vitro Assessment of Drug Interactions Results from in vitro studies indicate that deoxycholic acid does not inhibit or induce human cytochrome P450 (CYP) enzymes at clinically relevant concentrations. Deoxycholic acid does not inhibit the following transporters: P-gp, BCRP, MRP4, MRP2, OATP1B1, OATP2B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, NTCP, and ASBT. Specific Populations Hepatic Impairment KYBELLA has not been studied in subjects with hepatic impairment. Considering the intermittent dose frequency, the small dose administered that represents approximately 3% of the total bile acid pool, and the highly variable endogenous deoxycholic acid levels, the pharmacokinetics of deoxycholic acid following KYBELLA injection is unlikely to be influenced by hepatic impairment. Pharmacokinetic E ffects of Gender Deoxycholic acid pharmacokinetics were not influenced by gender."],"indications_and_usage":["1 INDICATIONS AND USAGE KYBELLA ® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. Limitations of use The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. KYBELLA is a cytolytic drug indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. ( 1 ) Limit ation s of use The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PR E CAUTIONS Marginal mandibular nerve (MMN) injury: Follow injection technique to avoid this injury. ( 2.3 , 5.1 ) Dysphagia may occur with KYBELLA use. Use in patients with pre-existing dysphagia may exacerbate the condition. ( 5.2 ) Submental hematoma/bruising occurs frequently after KYBELLA administration. Use with caution in patients who are being treated with antiplatelet or anticoagulant therapy or have coagulation abnormalities. ( 5.3 ) Avoid injecting in proximity to vulnerable anatomic structures due to the increased risk of tissue damage and vascular injury. ( 2.3 , 5.4 ) Injection site alopecia: Withhold subsequent treatments until resolution. ( 5.5 ) Injection site ulceration, necrosis, and infection: Do not administer to the affected area until complete resolution. ( 5.6 ) 5 . 1 Marginal mandibular nerve injury Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness (paresis), were reported during clinical trials. To avoid the potential for nerve injury, KYBELLA injection should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve. All marginal mandibular nerve injuries reported from the trials resolved spontaneously (range 1-298 days, median 44 days). 5 . 2 Dysphagia Difficulty swallowing (dysphagia) occurred in clinical trials in the setting of administration site reactions, e.g., pain, swelling, and induration of the submental area. Cases of dysphagia spontaneously resolved (range 1-81 days, median 3 days). Subjects with current or prior history of dysphagia were excluded from clinical trials. Avoid use of KYBELLA in these patients as current or prior history of dysphagia may exacerbate the condition. 5.3 Injection site hematoma /bruising In clinical trials, 72% of subjects treated with KYBELLA experienced injection site hematoma/bruising [see Adverse Reactions ( 6.1 ) ] . KYBELLA should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur. 5.4 Risk of injecting in proximity to vulnerable anatomic structure s To avoid potential tissue damage, KYBELLA should not be injected into or in close proximity (1-1.5 cm) to salivary glands, lymph nodes and muscles. Care should be taken to avoid inadvertent injection directly into an artery or a vein as it can result in vascular injury. 5.5 Injection site alopecia Cases of injection site alopecia have been reported with the administration of KYBELLA. The onset and duration of this adverse reaction may vary among individuals and may persist. Consider withholding subsequent treatments until resolution of the adverse reaction. 5.6 Injection site ulceration , necrosis , and infection Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis [see Injection Technique ( 2.3 )] . Cases of injection site ulceration, necrosis, and infection have been reported with the administration of KYBELLA. Some cases of injection site infection have included cellulitis and abscess requiring intravenous antibiotic treatment and incision and drainage. Do not administer KYBELLA into the affected area until complete resolution of the adverse reaction."],"clinical_studies_table":["<table ID=\"Table2\"><caption>Table 2. &#x2265; 2-Grade and &#x2265; 1-Grade Composite Clinician and Patient Response 12 Weeks After Final Treatment</caption><col width=\"222\"/><col width=\"90\"/><col width=\"90\"/><col width=\"90\"/><col width=\"90\"/><tbody><tr><td styleCode=\"Toprule Lrule Rrule \" valign=\"bottom\"/><td styleCode=\"Toprule Lrule Rrule \" colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Trial 1</content></td><td styleCode=\"Toprule Lrule Rrule \" colspan=\"2\" align=\"center\"><content styleCode=\"bold\">Trial 2</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" valign=\"bottom\"><content styleCode=\"bold\">Endpoint</content></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">KYBELLA</content>  (N=256)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">Placebo</content> (N=250)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">KYBELLA</content> (N=258)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\"><content styleCode=\"bold\">Placebo</content> (N=258)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">2-Grade Composite Response <sup>a</sup><sup> </sup></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">13.4%</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">&lt;0.1%</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">18.6%</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">3.0%</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">1-Grade Composite Response<sup> b</sup></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">70.0%</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">18.6%</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">66.5%</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">22.2%</td></tr></tbody></table>"],"nonclinical_toxicology":["1 3 NONCLINICAL TO X ICOLOGY 13.1 Carcinogenes i s, Mutagenes i s, Impairment of Fe r tility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of KYBELLA injection. KYBELLA was negative in a battery of in vitro (Ames test and chromosomal aberration assay in human lymphocytes) and in vivo (rat erythrocyte micronucleus assay) genetic toxicology assays. No effects on fertility were observed in male and female rats administered deoxycholic acid at subcutaneous doses up to 50 mg/kg (5 times the MRHD based on a mg/m 2 comparison) once weekly prior to and during the mating period and through gestation day 7 in female rats."],"adverse_reactions_table":["<table ID=\"Table1\"><caption>Table 1. Adverse Reactions in the Pooled Trials 1 and 2<sup>a</sup></caption><col width=\"147\"/><col width=\"109\"/><col width=\"126\"/><tbody><tr><td styleCode=\"Toprule Lrule Rrule \"> Adverse reactions</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">KYBELLA (N=513) n (%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">Placebo (N=506) n (%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Injection site reactions</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">492 (96%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">411 (81%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> edema/swelling</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">448 (87%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">218 (43%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> hematoma/bruising</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">368 (72%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">353 (70%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> pain</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">356 (70%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">160 (32%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> numbness</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">341 (66%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">29 (6%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> erythema</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">136 (27%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">91 (18%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> induration</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">120 (23%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">13 (3%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> paresthesia</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">70 (14%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">20 (4%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> nodule</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">68 (13%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">14 (3%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> pruritus</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">64 (12%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">30 (6%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> skin tightness</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">24 (5%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">6 (1%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> site warmth</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">22 (4%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">8 (2%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \"> nerve injury<sup> b</sup></td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">20 (4 %)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">1 (&lt;1%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Headache</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">41 (8%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">20 (4%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Oropharyngeal pain</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">15 (3%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">7 (1%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Hypertension</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">13 (3%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">7 (1%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Nausea</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">12 (2%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">3 (1%)</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \">Dysphagia</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">10 (2%)</td><td styleCode=\"Toprule Lrule Rrule \" align=\"center\">1 (&lt;1%)</td></tr></tbody></table>"],"information_for_patients":["1 7 PATIENT COUNSELING INFORMA T ION Advise the patient to read the FDA-approved patient labeling ( Patient Information ). Advise patients to contact their healthcare providers if patients begin to develop signs of marginal mandibular nerve paresis (e.g., asymmetric smile, facial muscle weakness), difficulty swallowing, or worsening of existing symptoms. Advise patients to contact their healthcare providers for development of erythema, pain, open sore(s) or drainage from the treatment area. Distributed by: AbbVie Inc. Manufactured for: AbbVie Inc. North Chicago, IL 60064 © 2024 AbbVie. All rights reserved. KYBELLA ® and its design are registered trademarks of Allergan Sales, LLC, an AbbVie company. Patented. See www.abbvie.com/patents v4.0USPI0101 Shape Description automatically generated"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION 0.2 mL injections spaced 1 cm apart until all sites in the planned treatment area have been injected. ( 2.1 ) Up to 50 injections or 10 mL may be injected in a single treatment. ( 2.1 ) Up to 6 single treatments may be administered at intervals no less than 1-month apart. ( 2.1 ) See General Considerations for Administration and Injection Technique before injection. ( 2.2 , 2.3 ) Figure 1. Avoid the Marginal Mandibular Nerve Area Figure 2. Sagittal View of Platysma Area Figure 3. Injection Pattern 2.1 Dos age KYBELLA injection is injected into subcutaneous fat tissue in the submental area using an area-adjusted dose of 2 mg/cm 2 . A single treatment consists of up to a maximum of 50 injections, 0.2 mL each (up to a total of 10 mL), spaced 1 cm apart. Up to 6 single treatments may be administered at intervals no less than 1 month apart. See General Considerations for Administration ( 2.2 ) and Injection Technique ( 2.3 ) before injection. 2.2 General Considerations for Administration KYBELLA should be administered by a healthcare professional. Screen patients for other potential causes of submental convexity/fullness (e.g., thyromegaly and cervical lymphadenopathy). Give careful consideration to the use of KYBELLA in patients with excessive skin laxity, prominent platysmal bands or other conditions for which reduction of submental fat may result in an aesthetically undesirable outcome. Use caution in patients who have had prior surgical or aesthetic treatment of the submental area. Changes in anatomy/landmarks or the presence of scar tissue may impact the ability to safely administer KYBELLA or to obtain the desired aesthetic result. KYBELLA is clear, colorless and free of particulate matter. Visually inspect KYBELLA vials for particulate matter and/or discoloration, and discard the vial if the solution is discolored and/or contains particulate matter. After use, discard any remaining solution in the vial. 2. 3 Injection Technique The safe and effective use of KYBELLA depends on the use of the correct number and locations for injections, proper needle placement, and administration techniques. Healthcare professionals administering KYBELLA must understand the relevant submental anatomy and associated neuromuscular structures in the area involved and any alterations to the anatomy due to prior surgical or aesthetic procedures [ see W a r n in g s a n d Preca u ti o ns ( 5 ) ]. Avoid injections near the area of the marginal mandibular nerve Needle placement with respect to the mandible is very important as it reduces the potential for injury to the marginal mandibular nerve, a motor branch of the facial nerve. Injury to the nerve presents as an asymmetrical smile due to paresis of lip depressor muscles [ see Warnings and Precautions ( 5.1 ) ] . To avoid injury to the marginal mandibular nerve: Do not inject above the inferior border of the mandible. Do not inject within a region defined by a 1-1.5 cm line below the inferior border (from the angle of the mandible to the mentum). Inject KYBELLA only within the target submental fat treatment area (see Figures 1 and 3 ). Figure 1. Avoid the Marginal Mandibular Nerve Area Avoid injection into the platysma Prior to each treatment session, palpate the submental area to ensure sufficient submental fat and to identify subcutaneous fat between the dermis and platysma (pre-platysmal fat) within the target treatment area ( Figure 2 ). The number of injections and the number of treatments should be tailored to the individual patient’s submental fat distribution and treatment goals. Figure 2 . Sagittal View of Platy s ma Area Injecting into the treatment area Use of ice/cold packs, topical and/or injectable local anesthesia (e.g., lidocaine) may enhance patient comfort. Outline the planned treatment area with a surgical pen and apply a 1 cm injection grid to mark the injection sites ( Figures 2 and 3 ). Figure 3 . Treatment Area and Injection Pattern Do not inject KYBELLA outside the defined parameters [see Warnings and Precautions ( 5.1 , 5.4 , 5.6 )] . Using a large bore needle, draw 1 mL of KYBELLA into a sterile 1 mL syringe and expel any air bubbles in the syringe barrel. Have the patient tense the platysma. Pinch the submental fat and, using a 30 gauge (or smaller) 0.5 inch needle, inject 0.2 mL of KYBELLA into the pre-platysmal fat (see Figure 2 ) next to each of the marked injection sites by advancing the needle perpendicular to the skin. Injections that are too superficial (into the dermis) may result in skin ulceration and necrosis. Do not withdraw the needle from the subcutaneous fat during injection as this could increase the risk of intradermal exposure and potential skin ulceration and necrosis. Avoid injecting into the post-platysmal fat by injecting KYBELLA into fat tissue at the depth of approximately mid-way into the subcutaneous fat layer ( Figure 2 ). If at any time resistance is met as the needle is inserted, indicating the possibility of contact with fascial or nonfat tissue, the needle must be withdrawn to an appropriate depth before the injection is administered. Avoid injecting into other tissues such as the muscle, salivary glands, lymph nodes; and artery or vein. Upon needle withdrawal, pressure may be applied to each injection site as necessary to minimize bleeding; an adhesive dressing may be applied."],"spl_product_data_elements":["KYBELLA Deoxycholic Acid DEOXYCHOLIC ACID DEOXYCHOLIC ACID BENZYL ALCOHOL SODIUM PHOSPHATE, DIBASIC SODIUM CHLORIDE SODIUM HYDROXIDE WATER HYDROCHLORIC ACID"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENG T HS Injection: 10 mg/mL. KYBELLA (deoxycholic acid) injection is a clear, colorless, sterile solution supplied in 2 mL vials intended for single patient use. Each milliliter of the solution contains 10 mg of deoxycholic acid. Injection: 10 mg/mL. ( 3 )"],"spl_patient_package_insert":["Patient Information KYBELLA ® (kye be lah) (deoxycholic acid ) injection What is KYBELLA ? KYBELLA is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called “double chin.” It is not known if KYBELLA is safe and effective for the treatment of fat outside of the submental area. It is not known if KYBELLA is safe and effective in children under 18 years of age. Do not receive KYBELLA if you have an infection in the treatment area. Before receiving KYBELLA , tell your healthcare provider about all of your medical conditions, including if you: have had or plan to have surgery on your face, neck, or chin have had cosmetic treatments on your face, neck, or chin have had or have medical conditions in or near the neck area have had or have trouble swallowing have bleeding problems are pregnant or plan to become pregnant. It is not known if KYBELLA will harm your unborn baby. are breastfeeding or plan to breastfeed. It is not known if KYBELLA passes into your breast milk. Tell your healthcare provider about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine). How will I receive KYBELLA ? KYBELLA is injected into the fat under your chin (up to 50 injections under your skin) by your healthcare provider. KYBELLA injections may be given at least 1 month apart. You and your healthcare provider will decide how many treatments you need. What are the possible side effects of KYBELLA ? KYBELLA can cause serious side effects, including: Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness . Trouble swallowing . Injection site problems including: a collection of blood under the skin (hematoma) or bruising damage to an artery or vein if KYBELLA is inadvertently injected into it hair loss open sores (ulcers) damage and tissue cell-death (necrosis) around the injection site infection Call your healthcare provider if you : begin to develop weakness in the muscles of your face, or your smile becomes uneven you have difficulty swallowing, or if any of the symptoms that you already have get worse develop redness, pain, open sores, or drainage at or from the treatment area The most common side effects of KYBELLA include: ● swelling ● redness ● pain ● areas of hardness in the treatment area ● numbness These are not all of the possible side effects of KYBELLA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. General information about the safe and effective use of KYBELLA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for more information about KYBELLA that is written for health professionals. What are the ingredients in KYBELLA ? Active ingredient: deoxycholic acid Inactive ingredients: benzyl alcohol, dibasic sodium phosphate, hydrochloric acid, sodium chloride, sodium hydroxide and water for injection, USP. Distributed by: AbbVie Inc. Manufactured for: AbbVie Inc. North Chicago, IL 60064 © 2024 AbbVie. All rights reserved. KYBELLA ® and its design are registered trademarks of Allergan Sales, LLC, an AbbVie company. Patented. See www.abbvie.com/patents For more information about KYBELLA go to www.mykybella.com. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 10/2024 v4.0PPI0101"],"use_in_specific_populations":["8 USE IN SPECIFIC POP U L A TIO N S 8 . 1 Preg n a n c y Risk Summary There are no adequate and well-controlled studies of KYBELLA injection in pregnant women to inform the drug-associated risk. In animal reproduction studies, no fetal harm was observed with the subcutaneous administration of deoxycholic acid to rats during organogenesis at doses up to 5 times the maximum recommended human dose (MRHD) of 100 mg [see Data] . The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk of major birth defects in the U.S. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies. Data Animal Data Embryofetal development studies have been performed in rats and rabbits using subcutaneous doses of deoxycholic acid administered during the period of organogenesis. For the basis of comparing animal to human doses, the MRHD is 1.7 mg/kg (100 mg/60 kg). No evidence of fetal harm was observed in rats at up to the highest dose tested (50 mg/kg) which is 5-fold higher than the MRHD of KYBELLA based on a mg/m 2 comparison. However, missing intermediate lung lobe was noted in rabbits at all dose levels tested including the lowest dose (10 mg/kg) which is 2-fold higher than the MRHD of KYBELLA based on a mg/m 2 comparison. These effects may be related to maternal toxicity, which was also seen at all dose levels tested. 8 . 2 Lactation Risk Summary There is no information available on the presence of synthetic deoxycholic acid in human milk, the effects of the drug on the breastfed infant or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KYBELLA and any potential adverse effects on the breastfed child from KYBELLA or from the underlying maternal condition. 8 . 4 Ped i atr i c Use Safety and effectiveness in patients below the age of 18 years have not been established and KYBELLA is not intended for use in children or adolescents. 8.5 Geriatric Use The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy."],"spl_patient_package_insert_table":["<table ID=\"PatientInformation\"><col width=\"344\"/><col width=\"164\"/><col width=\"247\"/><tbody><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\" align=\"center\"><content styleCode=\"bold\">Patient Information</content> <content styleCode=\"bold\">KYBELLA</content><content styleCode=\"bold\"><sup>&#xAE;</sup></content><content styleCode=\"bold\"> (kye be lah)</content> <content styleCode=\"bold\">(deoxycholic acid</content><content styleCode=\"bold\">)</content> <content styleCode=\"bold\">injection</content></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\"><content styleCode=\"bold\">What is KYBELLA</content><content styleCode=\"bold\">?</content> KYBELLA is a prescription medicine used in adults to improve the appearance and profile of moderate to severe fat below the chin (submental fat), also called &#x201C;double chin.&#x201D; It is not known if KYBELLA is safe and effective for the treatment of fat outside of the submental area. It is not known if KYBELLA is safe and effective in children under 18 years of age.</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\"><content styleCode=\"bold\">Do</content><content styleCode=\"bold\"> not receive KYBELLA if</content> you have an infection in the treatment area.</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\"><content styleCode=\"bold\">Before receiving </content><content styleCode=\"bold\">KYBELLA</content><content styleCode=\"bold\">, tell your healthcare provider about all of your medical conditions, including if you: </content> <list listType=\"unordered\" styleCode=\"Disc\"><item>have had or plan to have surgery on your face, neck, or chin </item><item>have had cosmetic treatments on your face, neck, or chin  </item><item>have had or have medical conditions in or near the neck area </item><item>have had or have trouble swallowing </item><item>have bleeding problems </item><item>are pregnant or plan to become pregnant. It is not known if KYBELLA will harm your unborn baby.  </item><item>are breastfeeding or plan to breastfeed. It is not known if KYBELLA passes into your breast milk. </item></list><content styleCode=\"bold\">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take a medicine that prevents the clotting of your blood (antiplatelet or anticoagulant medicine). </td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\"><content styleCode=\"bold\">How will I receive </content><content styleCode=\"bold\">KYBELLA</content><content styleCode=\"bold\">?</content><list listType=\"unordered\" styleCode=\"Disc\"><item>KYBELLA is injected into the fat under your chin (up to 50 injections under your skin) by your healthcare provider.  </item><item>KYBELLA injections may be given at least 1 month apart. You and your healthcare provider will decide how many treatments you need.</item></list></td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\"><content styleCode=\"bold\">What are the possible side effects of </content><content styleCode=\"bold\">KYBELLA</content><content styleCode=\"bold\">?</content> <content styleCode=\"bold\">KYBELLA </content><content styleCode=\"bold\">can cause serious side effects, including:</content> <list listType=\"unordered\" styleCode=\"Disc\"><item><content styleCode=\"bold\">Nerve injury in the jaw that can cause an uneven smile or facial muscle weakness</content><content styleCode=\"bold\">.</content><content styleCode=\"bold\"> </content> </item><item><content styleCode=\"bold\">Trouble swallowing</content><content styleCode=\"bold\">.</content> </item><item><content styleCode=\"bold\">Injection site problems including:</content><list listType=\"unordered\" styleCode=\"Circle\"><item>a collection of blood under the skin (hematoma) or bruising  </item><item>damage to an artery or vein if KYBELLA is inadvertently injected into it </item><item>hair loss </item><item>open sores (ulcers) </item><item>damage and tissue cell-death (necrosis) around the injection site </item><item>infection</item></list></item></list><content styleCode=\"bold\">Call your healthcare provider if you</content>: <list listType=\"unordered\" styleCode=\"Disc\"><item>begin to develop weakness in the muscles of your face, or your smile becomes uneven </item><item>you have difficulty swallowing, or if any of the symptoms that you already have get worse </item><item>develop redness, pain, open sores, or drainage at or from the treatment area </item></list><content styleCode=\"bold\">The most common side effects of </content><content styleCode=\"bold\">KYBELLA </content><content styleCode=\"bold\">include:</content></td></tr><tr><td styleCode=\"Lrule \"><content styleCode=\"bold\">&#x25CF; </content>swelling</td><td styleCode=\"Rrule \" colspan=\"2\"><content styleCode=\"bold\">&#x25CF; </content>redness</td></tr><tr><td styleCode=\"Lrule \"><content styleCode=\"bold\">&#x25CF;</content> pain</td><td styleCode=\"Rrule \" colspan=\"2\"><content styleCode=\"bold\">&#x25CF; </content>areas of hardness in the treatment area</td></tr><tr><td styleCode=\"Lrule \"><content styleCode=\"bold\">&#x25CF;</content> numbness</td><td styleCode=\"Rrule \" colspan=\"2\"/></tr><tr><td styleCode=\"Lrule Rrule \" colspan=\"3\">These are not all of the possible side effects of KYBELLA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\"><content styleCode=\"bold\">General information about the safe and effective use of </content><content styleCode=\"bold\">KYBELLA.</content> Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for more information about KYBELLA that is written for health professionals. </td></tr><tr><td styleCode=\"Toprule Lrule Rrule \" colspan=\"3\"><content styleCode=\"bold\">What are the ingredients in </content><content styleCode=\"bold\">KYBELLA</content><content styleCode=\"bold\">? </content> <content styleCode=\"bold\">Active ingredient:</content> deoxycholic acid  <content styleCode=\"bold\">Inactive ingredients:</content> benzyl alcohol, dibasic sodium phosphate, hydrochloric acid, sodium chloride, sodium hydroxide and water for injection, USP. </td></tr><tr><td styleCode=\"Lrule \" colspan=\"2\">Distributed by: AbbVie Inc. Manufactured for: AbbVie Inc. North Chicago, IL 60064 &#xA9; 2024 AbbVie. All rights reserved.  KYBELLA<sup>&#xAE;</sup> and its design are registered trademarks of Allergan Sales, LLC, an AbbVie  company.  Patented. See www.abbvie.com/patents For more information about KYBELLA go to www.mykybella.com. </td><td styleCode=\"Rrule \"><renderMultiMedia referencedObject=\"MM03000006\"/></td></tr></tbody></table>"],"package_label_principal_display_panel":["Principal Display Panel NDC: 61168-101-04 kybella ® (deoxycholic acid) injection 10 mg/mL 20 mg/2 mL (10 mg/mL) for subcutaneous use only Single use vials. Discard unused portion. Four ready-to-use vials. Do not dilute. Rx ONLY Allergan logo Principal Display Panel NDC: 61168-101-04 kybella® (deoxycholic acid) injection 10 mg/mL 20 mg/2 mL (10 mg/mL) for subcutaneous use only Single use vials. Discard unused portion. Four ready-to-use vials. Do not dilute. Rx ONLY"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenes i s, Mutagenes i s, Impairment of Fe r tility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of KYBELLA injection. KYBELLA was negative in a battery of in vitro (Ames test and chromosomal aberration assay in human lymphocytes) and in vivo (rat erythrocyte micronucleus assay) genetic toxicology assays. No effects on fertility were observed in male and female rats administered deoxycholic acid at subcutaneous doses up to 50 mg/kg (5 times the MRHD based on a mg/m 2 comparison) once weekly prior to and during the mating period and through gestation day 7 in female rats."]},"tags":[{"label":"Cytolytic Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"G-protein coupled bile acid receptor 1","category":"target"},{"label":"GPBAR1","category":"gene"},{"label":"NR1H4","category":"gene"},{"label":"FPR1","category":"gene"},{"label":"D11AX24","category":"atc"},{"label":"Subcutaneous","category":"route"},{"label":"Injection","category":"form"},{"label":"Generic Available","category":"availability"},{"label":"LOE Approaching","category":"status"},{"label":"Excess subcutaneous fat","category":"indication"},{"label":"Abbvie","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Cholagogues and Choleretics","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":469.51,"date":"","count":123,"signal":"Injection site swelling","source":"DrugCentral FAERS","actionTaken":"Reported 123 times (LLR=470)"},{"llr":301.671,"date":"","count":58,"signal":"Facial paresis","source":"DrugCentral FAERS","actionTaken":"Reported 58 times (LLR=302)"},{"llr":285.63,"date":"","count":54,"signal":"Injection site nodule","source":"DrugCentral FAERS","actionTaken":"Reported 54 times (LLR=286)"},{"llr":244.063,"date":"","count":55,"signal":"Nerve injury","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=244)"},{"llr":227.92,"date":"","count":113,"signal":"Swelling","source":"DrugCentral FAERS","actionTaken":"Reported 113 times (LLR=228)"},{"llr":209.032,"date":"","count":86,"signal":"Injection site pain","source":"DrugCentral FAERS","actionTaken":"Reported 86 times (LLR=209)"},{"llr":169.181,"date":"","count":40,"signal":"Injection site induration","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=169)"},{"llr":154.852,"date":"","count":43,"signal":"Injection site mass","source":"DrugCentral FAERS","actionTaken":"Reported 43 times (LLR=155)"},{"llr":142.695,"date":"","count":22,"signal":"Injection site hypoaesthesia","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=143)"}],"commonSideEffects":[{"effect":"Injection site edema/swelling","drugRate":"87%","severity":"serious","_validated":true},{"effect":"Injection site reactions","drugRate":"96%","severity":"serious","_validated":true},{"effect":"Injection site numbness","drugRate":"42%","severity":"serious","_validated":true},{"effect":"Injection site pain","drugRate":"16%","severity":"common","_validated":true},{"effect":"Injection site induration","drugRate":"13%","severity":"common","_validated":true},{"effect":"Hematoma/bruising","drugRate":"72%","severity":"serious","_validated":true},{"effect":"Erythema","drugRate":"27%","severity":"common","_validated":true},{"effect":"Paresthesia","drugRate":"14%","severity":"mild","_validated":true},{"effect":"Nodule","drugRate":"13%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"12%","severity":"mild","_validated":true},{"effect":"Site warmth","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Nerve injury","drugRate":"4%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"8%","severity":"common","_validated":true},{"effect":"Oropharyngeal pain","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Hypertension","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Nausea","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Dysphagia","drugRate":"2%","severity":"mild","_validated":true},{"effect":"Injection site hemorrhage","drugRate":"reported","severity":"unknown"},{"effect":"Injection site discoloration","drugRate":"reported","severity":"unknown"},{"effect":"Pre-syncope/syncope","drugRate":"reported","severity":"unknown"},{"effect":"Lymphadenopathy","drugRate":"reported","severity":"unknown"},{"effect":"Injection site urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Neck pain","drugRate":"reported","severity":"unknown"},{"effect":"Injection site ulceration","drugRate":"reported","severity":"unknown"},{"effect":"Necrosis","drugRate":"reported","severity":"unknown"},{"effect":"Alopecia","drugRate":"reported","severity":"unknown"},{"effect":"Scarring","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"There are no adequate and well-controlled studies of KYBELLA injection in pregnant women to inform the drug-associated risk. In animal reproduction studies, no fetal harm was observed with the subcutaneous administration of deoxycholic acid to rats during organogenesis at doses up to times the maximum recommended human dose (MRHD) of 100 mg. The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk of major birth defects in the U.S. general population is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.","Geriatric use":"The clinical trials of KYBELLA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.","Paediatric use":"Safety and effectiveness in patients below the age of 18 years have not been established and KYBELLA is not intended for use in children or adolescents."}},"trials":[],"aliases":[],"company":"AbbVie","patents":[{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Dec 10, 2027","useCode":"U-1690","territory":"US","drugProduct":false,"patentNumber":"7754230","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Feb 21, 2028","useCode":"U-1940","territory":"US","drugProduct":false,"patentNumber":"9949986","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Dec 10, 2027","useCode":"U-1690","territory":"US","drugProduct":false,"patentNumber":"7622130","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Feb 17, 2032","useCode":"U-1940","territory":"US","drugProduct":false,"patentNumber":"12161653","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Feb 21, 2028","useCode":"U-1940","territory":"US","drugProduct":false,"patentNumber":"9636349","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Feb 21, 2028","useCode":"U-1940","territory":"US","drugProduct":true,"patentNumber":"9522155","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Feb 21, 2028","useCode":"U-1690","territory":"US","drugProduct":true,"patentNumber":"8546367","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Feb 21, 2028","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8461140","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Mar 2, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8653058","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Mar 2, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8367649","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Mar 2, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8101593","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Feb 21, 2028","useCode":"","territory":"US","drugProduct":true,"patentNumber":"8883770","drugSubstance":false},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"May 16, 2028","useCode":"","territory":"US","drugProduct":false,"patentNumber":"8242294","drugSubstance":true},{"applNo":"N206333","source":"FDA Orange Book","status":"Active","expires":"Mar 2, 2030","useCode":"","territory":"US","drugProduct":true,"patentNumber":"10500214","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DEOXYCHOLIC ACID","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:45:38.840020+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:45:38.839946+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:45:45.244512+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEOXYCHOLIC ACID","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:45:45.730768+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:45:36.738269+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:45:36.738303+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:45:36.738309+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL514674/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:45:46.960012+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA206333","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:45:36.738313+00:00"}},"allNames":"kybella","offLabel":[],"synonyms":["choleic acid","deoxycholate","sodium deoxycholate","deoxycholic acid","kybella","ATX-101","dihydroxycholanoic acid","desoxycholic acid"],"timeline":[{"date":"2015-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from KYTHERA BIOPHARMS to Abbvie"},{"date":"2015-04-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Kythera Biopharms)"},{"date":"2021-04-02","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"},{"date":"2028-05-16","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 8242294 expires"}],"aiSummary":"Kybella, also known as deoxycholic acid, is a cytolytic agent originally developed by Kythera Biopharmaceuticals and currently owned by Abbvie. It targets the G-protein coupled bile acid receptor 1 to treat excess subcutaneous fat. Kybella is a small molecule modality that was FDA approved in 2015 for its approved indications. The commercial status of Kybella is patented, with only one generic manufacturer available. Key safety considerations include the potential for injection site reactions and nerve damage.","approvals":[{"date":"2015-04-29","orphan":false,"company":"KYTHERA BIOPHARMS","regulator":"FDA"}],"brandName":"Kybella","ecosystem":[{"indication":"Excess subcutaneous fat","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"G-protein coupled bile acid receptor 1","novelty":"Follow-on","targets":[{"gene":"GPBAR1","source":"DrugCentral","target":"G-protein coupled bile acid receptor 1","protein":"G-protein coupled bile acid receptor 1"},{"gene":"NR1H4","source":"DrugCentral","target":"Bile acid receptor","protein":"Bile acid receptor"},{"gene":"FPR1","source":"DrugCentral","target":"fMet-Leu-Phe receptor","protein":"fMet-Leu-Phe receptor"}],"modality":"Small Molecule","drugClass":"Cytolytic Agent [EPC]","explanation":"KYBELLA injection is cytolytic drug, which when injected into tissue physically destroys the cell membrane causing lysis.","oneSentence":"Kybella works by targeting and destroying excess fat cells through a process that involves disrupting the cell membrane.","technicalDetail":"Kybella, a G-protein coupled bile acid receptor 1 (TGR5) agonist, induces cell lysis through a process involving the activation of the TGR5 receptor, which leads to an increase in intracellular calcium and the subsequent disruption of the cell membrane.","_target_confidence":0.5},"commercial":{"launchDate":"2015","_launchSource":"DrugCentral (FDA 2015-04-29, KYTHERA BIOPHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4988","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DEOXYCHOLIC%20ACID","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEOXYCHOLIC ACID","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:27:57.244547","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:45:50.527817+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"minoxidil","drugSlug":"minoxidil","fdaApproval":"1979-10-18","genericCount":22,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"calcium gluconate","drugSlug":"calcium-gluconate","fdaApproval":"","patentExpiry":"Jul 25, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"magnesium sulfate","drugSlug":"magnesium-sulfate","fdaApproval":"1981-10-06","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mequinol","drugSlug":"mequinol","fdaApproval":"1999-12-10","relationship":"same-class"},{"drugName":"finasteride","drugSlug":"finasteride","fdaApproval":"1992-06-19","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"hydroquinone","drugSlug":"hydroquinone","fdaApproval":"2002-01-18","relationship":"same-class"},{"drugName":"pyrithione zinc","drugSlug":"pyrithione-zinc","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"monobenzone","drugSlug":"monobenzone","fdaApproval":"1952-11-10","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"eflornithine","drugSlug":"eflornithine","fdaApproval":"1990-11-28","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"diclofenac","drugSlug":"diclofenac","fdaApproval":"1988-07-28","patentExpiry":"Apr 23, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"brimonidine","drugSlug":"brimonidine","fdaApproval":"1996-09-06","patentExpiry":"Mar 25, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ivermectin","drugSlug":"ivermectin","fdaApproval":"1996-11-22","patentExpiry":"Mar 13, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"hydrogen peroxide","drugSlug":"hydrogen-peroxide","fdaApproval":"","patentExpiry":"Jul 4, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"caffeine","drugSlug":"caffeine","fdaApproval":"1948-11-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"oxymetazoline","drugSlug":"oxymetazoline","fdaApproval":"1986-05-30","patentExpiry":"May 2, 2028","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"deoxycholic acid","indications":{"approved":[{"name":"Excess subcutaneous fat","source":"DrugCentral","snomedId":248302001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Abbvie","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"minoxidil","brandName":"minoxidil","genericName":"minoxidil","approvalYear":"1979","relationship":"same-class"},{"drugId":"calcium-gluconate","brandName":"calcium gluconate","genericName":"calcium gluconate","approvalYear":"","relationship":"same-class"},{"drugId":"magnesium-sulfate","brandName":"magnesium sulfate","genericName":"magnesium sulfate","approvalYear":"1981","relationship":"same-class"},{"drugId":"mequinol","brandName":"mequinol","genericName":"mequinol","approvalYear":"1999","relationship":"same-class"},{"drugId":"finasteride","brandName":"finasteride","genericName":"finasteride","approvalYear":"1992","relationship":"same-class"},{"drugId":"hydroquinone","brandName":"hydroquinone","genericName":"hydroquinone","approvalYear":"2002","relationship":"same-class"},{"drugId":"pyrithione-zinc","brandName":"pyrithione zinc","genericName":"pyrithione zinc","approvalYear":"","relationship":"same-class"},{"drugId":"monobenzone","brandName":"monobenzone","genericName":"monobenzone","approvalYear":"1952","relationship":"same-class"},{"drugId":"eflornithine","brandName":"eflornithine","genericName":"eflornithine","approvalYear":"1990","relationship":"same-class"},{"drugId":"diclofenac","brandName":"diclofenac","genericName":"diclofenac","approvalYear":"1988","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06783621","phase":"PHASE4","title":"A Study to Evaluate Patient Satisfaction With the Overall Face and Neck Appearance After Combined Treatment of OnabotulinumtoxinA, JUVÉDERM® Products, KYBELLA, CoolSculpting Elite and SkinMedica Products","status":"COMPLETED","sponsor":"AbbVie","startDate":"2025-01-16","conditions":["Facial Contouring"],"enrollment":130,"completionDate":"2026-02-26"},{"nctId":"NCT06517862","phase":"PHASE4","title":"Efficacy & Safety of Oral Adjuvants to Phototherapy in Neonatal Hyperbilirubinemia","status":"RECRUITING","sponsor":"Amira Adel Fouly","startDate":"2024-09-01","conditions":["Neonatal Hyperbilirubinemia"],"enrollment":80,"completionDate":"2026-06-30"},{"nctId":"NCT03724175","phase":"PHASE2,PHASE3","title":"The Role of Secondary Bile Acids in Intestinal Inflammation","status":"TERMINATED","sponsor":"Stanford University","startDate":"2019-08-26","conditions":["Ulcerative Colitis","Pouchitis"],"enrollment":2,"completionDate":"2026-03-02"},{"nctId":"NCT06756490","phase":"PHASE1","title":"A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation","status":"RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2024-12-26","conditions":["Moderate or Severe Submental Fullness"],"enrollment":30,"completionDate":"2027-05-31"},{"nctId":"NCT07378761","phase":"PHASE2","title":"Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2026-02","conditions":["Immune-Mediated Cholestasis"],"enrollment":94,"completionDate":"2028-08"},{"nctId":"NCT07004010","phase":"NA","title":"Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat","status":"COMPLETED","sponsor":"Espad Pharmed","startDate":"2024-08-01","conditions":["Flank Fat"],"enrollment":30,"completionDate":"2024-12-30"},{"nctId":"NCT05751967","phase":"PHASE3","title":"Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2023-02-22","conditions":["Primary Biliary Cholangitis"],"enrollment":150,"completionDate":"2027-12-01"},{"nctId":"NCT06755541","phase":"PHASE3","title":"Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-01-30","conditions":["Primary Biliary Cholangitis (PBC)"],"enrollment":150,"completionDate":"2035-12"},{"nctId":"NCT00200343","phase":"PHASE3","title":"Efficacy and Safety Study of Ursodeoxycholic Acid to Treat Chronic Hepatitis C","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2002-07","conditions":["Chronic Hepatitis C"],"enrollment":596,"completionDate":"2004-12"},{"nctId":"NCT07296458","phase":"PHASE3","title":"FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy","status":"RECRUITING","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2025-12-15","conditions":["Primary Biliary Cholangitis (PBC)"],"enrollment":132,"completionDate":"2028-12-31"},{"nctId":"NCT06091787","phase":"NA","title":"Effect of Ursodeoxycholic Acid Supplementation on Liver Regeneration on Right Lobe Donor Hepatectomy","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-01","conditions":["Liver Regeneration","Ursodeoxycholic Acid","Partial Liver Resection"],"enrollment":90,"completionDate":"2024-11-30"},{"nctId":"NCT06922669","phase":"NA","title":"Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-06-24","conditions":["Drug Induced Liver Injury"],"enrollment":232,"completionDate":"2027-09-30"},{"nctId":"NCT06525389","phase":"PHASE3","title":"Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-04-01","conditions":["Talaromycosis"],"enrollment":428,"completionDate":"2031-11-01"},{"nctId":"NCT07273734","phase":"NA","title":"UDCA to Prevent Post-TIPS Hepatic Encephalopathy","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-01-01","conditions":["Hepatic Encephalopathy (HE)","TIPS"],"enrollment":270,"completionDate":"2027-12-31"},{"nctId":"NCT07110987","phase":"NA","title":"The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia","status":"RECRUITING","sponsor":"Tishreen University Hospital","startDate":"2025-06-26","conditions":["Hyperbilirubinemia, Neonatal Indirect"],"enrollment":70,"completionDate":"2027-03-01"},{"nctId":"NCT06610760","phase":"PHASE4","title":"Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2024-11-12","conditions":["Gastric Intestinal Metaplasia"],"enrollment":196,"completionDate":"2026-10-31"},{"nctId":"NCT07237425","phase":"PHASE1","title":"Intralesional Ronkyla Plus Injection for the Treatment of Superficial Lipoma","status":"RECRUITING","sponsor":"Glonova Pharma Co., Ltd","startDate":"2025-11-14","conditions":["Lipoma","Submental Fullness"],"enrollment":56,"completionDate":"2027-01-14"},{"nctId":"NCT06591468","phase":"PHASE2,PHASE3","title":"A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics","status":"ENROLLING_BY_INVITATION","sponsor":"Han Ying","startDate":"2024-10-30","conditions":["Primary Biliary Cholangitis (PBC)"],"enrollment":244,"completionDate":"2027-12-31"},{"nctId":"NCT06591455","phase":"EARLY_PHASE1","title":"A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis","status":"COMPLETED","sponsor":"Han Ying","startDate":"2024-09-14","conditions":["Primary Biliary Cholangitis (PBC)"],"enrollment":30,"completionDate":"2025-08-18"},{"nctId":"NCT06132165","phase":"PHASE1","title":"Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2024-03-01","conditions":["Neurofibromatosis 1"],"enrollment":13,"completionDate":"2025-07-31"},{"nctId":"NCT06300502","phase":"PHASE1","title":"Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)","status":"ENROLLING_BY_INVITATION","sponsor":"Massachusetts General Hospital","startDate":"2025-04-08","conditions":["Neurofibromas, Cutaneous","Neurofibromatosis 1"],"enrollment":15,"completionDate":"2026-02"},{"nctId":"NCT06884748","phase":"EARLY_PHASE1","title":"Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-12-01","conditions":["Clostridioides Difficile Infection"],"enrollment":30,"completionDate":"2028-05-01"},{"nctId":"NCT07191756","phase":"","title":"Amphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Qiu Ye","startDate":"2025-05-15","conditions":["Mucormycosis"],"enrollment":150,"completionDate":"2025-09-25"},{"nctId":"NCT06684106","phase":"NA","title":"Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2024-11-25","conditions":["Hyperlipidemia","Ursodeoxycholic Acid","Statin Therapy","Glucose Intolerance"],"enrollment":128,"completionDate":"2027-06-01"},{"nctId":"NCT06509438","phase":"NA","title":"Effectiveness and Safety Evaluation of Embella (Deoxycholic Acid, by Espad Pharmed Co.) in Management of Submental Fat","status":"COMPLETED","sponsor":"Espad Pharmed","startDate":"2023-04-10","conditions":["Submental Fullness"],"enrollment":20,"completionDate":"2024-01-01"},{"nctId":"NCT02314208","phase":"PHASE2","title":"Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2015-01-08","conditions":["Spastic Paraplegia, Hereditary"],"enrollment":12,"completionDate":"2018-01-01"},{"nctId":"NCT06414512","phase":"PHASE2","title":"Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2024-04-09","conditions":["Cryptococcal Meningitis"],"enrollment":48,"completionDate":"2024-10-02"},{"nctId":"NCT07102979","phase":"NA","title":"Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response","status":"ENROLLING_BY_INVITATION","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-01","conditions":["Liver Cirrhosis"],"enrollment":150,"completionDate":"2025-12-31"},{"nctId":"NCT07068191","phase":"NA","title":"Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","status":"RECRUITING","sponsor":"Phenomen Pharma","startDate":"2025-06-19","conditions":["Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","Hepatomegaly","Nonalcoholic Fatty Liver (NAFL)","Nonalcoholic Fatty Liver Disease (NAFLD)","Fatty Liver","Fatty Liver, Alcoholic","Fatty Liver, Nonalcoholic","Fatty Liver Disease"],"enrollment":90,"completionDate":"2025-08"},{"nctId":"NCT07072949","phase":"PHASE1","title":"The Impact of Ursodeoxycholic Acid and Probiotics on Metabolic Outcomes in Type 2 Diabetic Patients Taking Metformin","status":"COMPLETED","sponsor":"University of Banja Luka","startDate":"2023-01-03","conditions":["Type 2 Diabetes Mellitus"],"enrollment":90,"completionDate":"2024-01-31"},{"nctId":"NCT00873275","phase":"PHASE1","title":"Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2009-03-11","conditions":["Colorectal Cancer"],"enrollment":11,"completionDate":"2025-02-26"},{"nctId":"NCT07014163","phase":"NA","title":"Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) Injection in the Management of Superficial Lipomas","status":"RECRUITING","sponsor":"Espad Pharmed","startDate":"2024-05-21","conditions":["Lipoma"],"enrollment":10,"completionDate":"2026-06-20"},{"nctId":"NCT06294847","phase":"PHASE3","title":"Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2024-08-20","conditions":["Retinal Detachment"],"enrollment":120,"completionDate":"2027-11"},{"nctId":"NCT03284034","phase":"NA","title":"Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2017-11-27","conditions":["Upper Back Fat"],"enrollment":8,"completionDate":"2020-06-08"},{"nctId":"NCT04407650","phase":"PHASE4","title":"Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College London","startDate":"2021-07-01","conditions":["Gestational Diabetes"],"enrollment":64,"completionDate":"2025-05-31"},{"nctId":"NCT06926569","phase":"NA","title":"Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2025-05-01","conditions":["HIV/AIDS-associated Talaromycosis"],"enrollment":116,"completionDate":"2026-05-01"},{"nctId":"NCT06918080","phase":"PHASE4","title":"Hepatoprotective Measures for Children at High Risk of NAFLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-11-19","conditions":["Non Alcoholic Fatty Liver Diseases (NAFLD)","Obesity and Overweight","Acute Lymphoblastic Leukemia"],"enrollment":200,"completionDate":"2025-07"},{"nctId":"NCT04650243","phase":"PHASE4","title":"Clinical Research of Tapering UDCA in PBC Patients With a Complete Response","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2020-01-21","conditions":["Primary Biliary Cholangitis"],"enrollment":90,"completionDate":"2025-05"},{"nctId":"NCT03188146","phase":"","title":"Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2017-05-01","conditions":["Primary Biliary Cholangitis (PBC)"],"enrollment":57,"completionDate":"2025-02-15"},{"nctId":"NCT04924868","phase":"PHASE3","title":"Ursodeoxycolic Acid for the Prevention of Relapsing Complications After Gallstone Acute Pancreatitis","status":"RECRUITING","sponsor":"Hospital General Universitario de Alicante","startDate":"2021-11-10","conditions":["Acute Pancreatitis Due to Gallstones"],"enrollment":332,"completionDate":"2027-07-01"},{"nctId":"NCT06842472","phase":"PHASE2","title":"PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-02","conditions":["Breast Cancer"],"enrollment":70,"completionDate":"2029-12"},{"nctId":"NCT05659654","phase":"PHASE1,PHASE2","title":"The Application of Ursodeoxycholic Acid for the Prevention of SARS-CoV-2 Infection (COVID-19)","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2022-12-16","conditions":["COVID-19"],"enrollment":95,"completionDate":"2023-03-08"},{"nctId":"NCT04730583","phase":"PHASE1","title":"Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-06-02","conditions":["Cutaneous Neurofibroma"],"enrollment":34,"completionDate":"2024-04-19"},{"nctId":"NCT06120036","phase":"PHASE1","title":"Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2022-12-06","conditions":["Neurofibromatosis 1"],"enrollment":20,"completionDate":"2025-01-09"},{"nctId":"NCT06260748","phase":"PHASE3","title":"A Study of Chenodeoxycholic Acid (CDCA) in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)","status":"WITHDRAWN","sponsor":"Leadiant Biosciences, Inc.","startDate":"2024-05-27","conditions":["Cerebrotendinous Xanthomatoses"],"enrollment":0,"completionDate":"2025-12-31"},{"nctId":"NCT05925309","phase":"NA","title":"Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-07-01","conditions":["Biliary Atresia","Cholangitis","Anti-Bacterial Agents"],"enrollment":356,"completionDate":"2027-07-31"},{"nctId":"NCT06629909","phase":"PHASE1","title":"Safety and Feasibility of Human Umbilical Cord Mesenchymal Stem Cell-Derived Secretome in the Treatment of Liver Cirrhosis: a Comprehensive Evaluation of Fibrosis Reduction, Immunomodulation, and Hepatic Regeneration: a Single Center, Randomized, Phase I Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Baermed","startDate":"2024-12-01","conditions":["Liver Cirrhosis"],"enrollment":54,"completionDate":"2026-10-31"},{"nctId":"NCT00909610","phase":"PHASE1","title":"Ursodiol Tablets 500 mg Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-12","conditions":["Healthy"],"enrollment":80,"completionDate":"2007-01"},{"nctId":"NCT00909753","phase":"PHASE1","title":"Ursodiol 500 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2006-09","conditions":["Healthy"],"enrollment":92,"completionDate":"2006-10"},{"nctId":"NCT04640571","phase":"PHASE4","title":"Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-04-01","conditions":["Bile Salt Export Pump (BSEP) Transporter","Polysorbate 80"],"enrollment":18,"completionDate":"2021-11-01"},{"nctId":"NCT03004118","phase":"PHASE4","title":"Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2017-01","conditions":["Functional Dyspepsia"],"enrollment":16,"completionDate":"2025-11"},{"nctId":"NCT06278090","phase":"","title":"Impact of Ursodeoxycholic Acid Treatment on the Gallbladder Polyp Evolution","status":"RECRUITING","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2024-03-01","conditions":["Gallbladder Polyp"],"enrollment":36,"completionDate":"2026-07"},{"nctId":"NCT06447402","phase":"PHASE3","title":"A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2024-06-03","conditions":["Chronic Pulmonary Aspergillosis","CPA","Aspergilloma"],"enrollment":196,"completionDate":"2026-08-31"},{"nctId":"NCT05973370","phase":"PHASE2","title":"Evaluating the Effect of Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2023-05-01","conditions":["Rheumatoid Arthritis"],"enrollment":60,"completionDate":"2024-05-30"},{"nctId":"NCT05526807","phase":"NA","title":"Ursodeoxycholic Acid in C. Difficile Infection","status":"TERMINATED","sponsor":"Nottingham University Hospitals NHS Trust","startDate":"2019-05-08","conditions":["Clostridioides Difficile Infection"],"enrollment":6,"completionDate":"2023-12-31"},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":["Ewing's Family Tumors","Renal Tumors","Hepatoblastoma","Rhabdomyosarcoma","Soft Tissue Sarcoma","Primary Malignant Brain Neoplasms","Retinoblastoma","Medulloblastoma","Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)","Atypical Teratoid/Rhabdoid Tumor (AT/RT)","CNS Tumors","Germ Cell Tumors"],"enrollment":44,"completionDate":"2024-02-01"},{"nctId":"NCT00550862","phase":"PHASE2","title":"Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2007-10","conditions":["Liver Cirrhosis, Biliary"],"enrollment":165,"completionDate":"2010-12"},{"nctId":"NCT06180057","phase":"PHASE1","title":"Bioequivalence Study to Compare Chenodeoxycholic Acid Capsules (250mg Chenodeoxycholic Acid) Versus Chenodeoxycholic Acid Leadiant 250 mg Hard Capsules (250mg Chenodeoxycholic Acid)","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2022-06-12","conditions":["Cerebrotendinous Xanthomatoses"],"enrollment":24,"completionDate":"2022-08-15"},{"nctId":"NCT04502381","phase":"PHASE2","title":"Combined Inhalational With Intravenous Amphotericin B Versus Intravenous Amphotericin B Alone for Pulmonary Mucormycosis","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-07-01","conditions":["Pulmonary Mucormycosis"],"enrollment":30,"completionDate":"2021-12-30"},{"nctId":"NCT06127355","phase":"PHASE3","title":"Gestational Treatment With Ursodeoxycholic Acid Compared to Placebo to Reduce Severity of Gestational Diabetes Mellitus Diagnosed at 24-28 Weeks' Gestation","status":"COMPLETED","sponsor":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia","startDate":"2021-03-03","conditions":["Gestational Diabetes"],"enrollment":113,"completionDate":"2022-05-10"},{"nctId":"NCT05902468","phase":"PHASE2,PHASE3","title":"Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Tanta University","startDate":"2023-06-28","conditions":["Diabetes Mellitus, Type 2"],"enrollment":88,"completionDate":"2024-11-28"},{"nctId":"NCT03602976","phase":"PHASE2","title":"Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis","status":"TERMINATED","sponsor":"Ethan Weinberg","startDate":"2018-08-20","conditions":["Hepatic Sarcoidosis, Elevated Alkaline Phosphatase"],"enrollment":7,"completionDate":"2022-01-12"},{"nctId":"NCT04076527","phase":"","title":"Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis","status":"UNKNOWN","sponsor":"University of Leipzig","startDate":"2019-09-19","conditions":["PBC","Primary Biliary Cholangitis"],"enrollment":1200,"completionDate":"2024-03"},{"nctId":"NCT05416580","phase":"PHASE3","title":"Efficacy of Ursodeoxycholic Acid (UDCA) in Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"University of Banja Luka","startDate":"2022-09-12","conditions":["Diabetes Mellitus, Type 2"],"enrollment":60,"completionDate":"2024-04"},{"nctId":"NCT05849558","phase":"PHASE4","title":"Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients","status":"UNKNOWN","sponsor":"MinaPharm Pharmaceuticals","startDate":"2022-02-22","conditions":["Chronic Liver Disease"],"enrollment":297,"completionDate":"2023-12-31"},{"nctId":"NCT05832697","phase":"PHASE1","title":"An Exploratory Clinical Trial to Evaluate and Compare Safety and Pharmacokinetic Characteristics After Administration of the DWJ1439, DWJ1464, DWC202108 or DWC202109 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-01-27","conditions":["Healthy Subject"],"enrollment":44,"completionDate":"2023-01-30"},{"nctId":"NCT05812612","phase":"","title":"UDCA in the Treatment of COVID-19 Infection and Its Clinical Prognosis in Patients With Autoimmune Liver Disease","status":"UNKNOWN","sponsor":"Beijing Ditan Hospital","startDate":"2023-01-30","conditions":["COVID-19 Infection"],"enrollment":2000,"completionDate":"2023-12-30"},{"nctId":"NCT05690646","phase":"PHASE4","title":"Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-01-28","conditions":["Cardiac Surgery"],"enrollment":491,"completionDate":"2026-01-06"},{"nctId":"NCT04834557","phase":"PHASE2","title":"Evaluating the Effect of Digoxin and Ursodeoxycholic Acid in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2021-11-01","conditions":["Rheumatoid Arthritis"],"enrollment":90,"completionDate":"2022-09-30"},{"nctId":"NCT05753852","phase":"PHASE3","title":"Open Label Extension of TUDCA-ALS Study","status":"UNKNOWN","sponsor":"Humanitas Mirasole SpA","startDate":"2021-10-25","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":184,"completionDate":"2025-03-31"},{"nctId":"NCT04542473","phase":"PHASE2,PHASE3","title":"Pancreatic Enzymes and Bile Acids in Acutely Ill Severely Malnourished Children","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-07-01","conditions":["SEPSIS","MALNUTRITION, CHILD"],"enrollment":400,"completionDate":"2024-06-30"},{"nctId":"NCT04531878","phase":"PHASE2,PHASE3","title":"BSEP Function Rescue During Childhood Inhereditary Cholestatic Diseases","status":"WITHDRAWN","sponsor":"Children's Hospital of Fudan University","startDate":"2023-02-08","conditions":["Hereditary Diseases","Cholestasis, Intrahepatic"],"enrollment":0,"completionDate":"2023-02-08"},{"nctId":"NCT05467553","phase":"PHASE2","title":"A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-02-24","conditions":["Hepatitis D"],"enrollment":30,"completionDate":"2025-08-31"},{"nctId":"NCT04910178","phase":"PHASE4","title":"Follow-up of NAFLD Patients With MRI-PDFF","status":"COMPLETED","sponsor":"Asmaa Abdelfattah Elsayed","startDate":"2020-12-01","conditions":["Diabetes Type 2","NAFLD"],"enrollment":80,"completionDate":"2021-12-30"},{"nctId":"NCT04810156","phase":"PHASE2","title":"Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis","status":"UNKNOWN","sponsor":"Inge Marie Svane","startDate":"2021-04-07","conditions":["Hepatitis, Drug-Induced"],"enrollment":60,"completionDate":"2025-11-07"},{"nctId":"NCT05642624","phase":"","title":"The PK/PD of Deoxycholic Acid Amphotericin B in Invasive Fungal Infection Patients With Sepsis/Septic Shock","status":"COMPLETED","sponsor":"Southeast University, China","startDate":"2019-02-28","conditions":["Fungal Infection"],"enrollment":20,"completionDate":"2022-06-28"},{"nctId":"NCT05500937","phase":"PHASE2,PHASE3","title":"Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2021-03-01","conditions":["Diabetes Mellitus"],"enrollment":1000,"completionDate":"2024-12-31"},{"nctId":"NCT05499026","phase":"","title":"Safety and Efficacy of CDCA in CTX Chenodeoxycholic Acid (CDCA) in Patients Affected by Cerebrotendinous Xanthomatosis (CTX)","status":"COMPLETED","sponsor":"Leadiant Biosciences Ltd.","startDate":"2014-12-09","conditions":["Cerebrotendinous Xanthomatoses"],"enrollment":28,"completionDate":"2015-06-03"},{"nctId":"NCT03168555","phase":"PHASE4","title":"Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2017-06-22","conditions":["Bile Acid Malabsorption","Cholelithiasis"],"enrollment":23,"completionDate":"2019-05-15"},{"nctId":"NCT04841551","phase":"PHASE4","title":"Kybella for the Treatment of Flank Fat (FF)","status":"COMPLETED","sponsor":"Beer, Kenneth R., M.D., PA","startDate":"2021-07-22","conditions":["Adiposity"],"enrollment":10,"completionDate":"2022-03-02"},{"nctId":"NCT02967250","phase":"PHASE1","title":"Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-04-01","conditions":["Parkinson Disease"],"enrollment":5,"completionDate":"2022-02-28"},{"nctId":"NCT03844100","phase":"PHASE1,PHASE2","title":"Effectiveness and Safety in Administrating CNU® Capsule to Refractory Functional Dyspepsia Patients","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2019-11-01","conditions":["Dyspepsia","Biliary Dysplasia"],"enrollment":37,"completionDate":"2021-08-04"},{"nctId":"NCT02748616","phase":"PHASE4","title":"C. Difficile and Ursodiol","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-03-01","conditions":["Diarrhea"],"enrollment":9,"completionDate":"2020-01-31"},{"nctId":"NCT03510598","phase":"PHASE4","title":"Submental Study (Sequential Treatment Approach)","status":"COMPLETED","sponsor":"Zeltiq Aesthetics","startDate":"2018-03-27","conditions":["Body Fat Disorder"],"enrollment":16,"completionDate":"2018-12-08"},{"nctId":"NCT00885703","phase":"PHASE1,PHASE2","title":"High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-04-16","conditions":["Cryptococcal Meningitis","HIV Infections"],"enrollment":168,"completionDate":"2017-01-12"},{"nctId":"NCT02936596","phase":"NA","title":"Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome","status":"UNKNOWN","sponsor":"Xiaoli Fan","startDate":"2016-12","conditions":["Hepatitis, Autoimmune","Cholangitis","Liver Cirrhosis, Biliary","Cholestasis"],"enrollment":53,"completionDate":"2022-06-01"},{"nctId":"NCT02021110","phase":"PHASE2","title":"Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-12","conditions":["Polycystic Liver Disease","Polycystic Kidney, Autosomal Dominant"],"enrollment":34,"completionDate":"2015-10"},{"nctId":"NCT05043194","phase":"NA","title":"Ursodeoxycholic Acid Prevents Total Parenteral Nutrition Cholestasis","status":"UNKNOWN","sponsor":"Wei Liu","startDate":"2021-01-01","conditions":["Cholestasis of Parenteral Nutrition"],"enrollment":80,"completionDate":"2022-07-30"},{"nctId":"NCT02965911","phase":"PHASE1,PHASE2","title":"Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA","status":"WITHDRAWN","sponsor":"Beijing 302 Hospital","startDate":"2016-01","conditions":["Primary Biliary Cirrhosis"],"enrollment":0,"completionDate":"2021-09-08"},{"nctId":"NCT04281082","phase":"","title":"Genetic Polymorphisms of ABCB11 and ABCB4 in Women With Intrahepatic Cholestasis of Pregnancy (ICP) and in Their First Degree Relatives","status":"UNKNOWN","sponsor":"Alexandra Hospital, Athens, Greece","startDate":"2018-01-01","conditions":["Cholestasis of Pregnancy"],"enrollment":50,"completionDate":"2022-01-31"},{"nctId":"NCT04977661","phase":"PHASE4","title":"Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2020-02-01","conditions":["Nonalcoholic Steatohepatitis (NASH)"],"enrollment":102,"completionDate":"2021-01-10"},{"nctId":"NCT00059202","phase":"PHASE2,PHASE3","title":"Trial of High-dose Urso in Primary Sclerosing Cholangitis","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2002-07","conditions":["Primary Sclerosing Cholangitis"],"enrollment":150,"completionDate":"2008-06"},{"nctId":"NCT03201952","phase":"PHASE1","title":"Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-02-01","conditions":["Glucose Intolerance","Gastric Bypass Surgery"],"enrollment":2,"completionDate":"2020-05-01"},{"nctId":"NCT04089722","phase":"PHASE4","title":"Efficacy and Safety of Deoxycholic Acid Injections for Removal of Adipose Tissue in the \"Bra Strap Fat\" Region","status":"COMPLETED","sponsor":"Juva Skin & Laser Center","startDate":"2019-07-26","conditions":["Brassiere Strap Fat (BSF)","Bra Strap Fat (BSF)"],"enrollment":22,"completionDate":"2020-10-22"},{"nctId":"NCT04617561","phase":"PHASE4","title":"Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-11-01","conditions":["Hepatitis, Autoimmune","Primary Biliary Cholangitis"],"enrollment":90,"completionDate":"2022-11-01"},{"nctId":"NCT04786795","phase":"PHASE4","title":"MITE in the Treatment of Dyspepsia After Cholecystectomy","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2021-03-01","conditions":["Patients With Dyspeptic Symptoms After Cholecystectomy"],"enrollment":990,"completionDate":"2022-02"},{"nctId":"NCT03678480","phase":"PHASE2","title":"A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC)","status":"WITHDRAWN","sponsor":"HighTide Biopharma Pty Ltd","startDate":"2021-03-01","conditions":["Primary Sclerosing Cholangitis","Cholangitis","Cholangitis, Sclerosing","Bile Duct Diseases","Biliary Tract Diseases","Digestive System Diseases","Adolescent"],"enrollment":0,"completionDate":"2021-11-04"},{"nctId":"NCT04751188","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis","status":"UNKNOWN","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2020-10-02","conditions":["Primary Biliary Cirrhosis"],"enrollment":11,"completionDate":"2021-07"},{"nctId":"NCT03664596","phase":"NA","title":"Therapeutic And Dietary Effects Of The Sublimated Mare's Milk Supplement In Patients With Non-Alcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Medical Centre Hospital of the President's Affairs Administration, Republic of Kazakhstan","startDate":"2018-08-01","conditions":["Non-alcoholic Steatohepatitis"],"enrollment":80,"completionDate":"2020-12-01"},{"nctId":"NCT04072640","phase":"EARLY_PHASE1","title":"Three Induction Treatments on Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-01-25","conditions":["Cryptococcal Meningitis","HIV/AIDS"],"enrollment":120,"completionDate":"2022-12-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Subcutaneous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","productName":"KYBELLA"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"14975","NDDF":"001205","UNII":"005990WHZZ","CHEBI":"CHEBI:28834","VANDF":"4018928","INN_ID":"9540","RXNORM":"1367220","UMLSCUI":"C0011479","chemblId":"CHEMBL514674","ChEMBL_ID":"CHEMBL406393","DRUGBANK_ID":"DB03619","PDB_CHEM_ID":" DHO","PUBCHEM_CID":"222528","SNOMEDCT_US":"434444004","IUPHAR_LIGAND_ID":"610","MESH_DESCRIPTOR_UI":"D003840"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, SOLUTION","route":"SUBCUTANEOUS","company":"Kythera Biopharmaceuticals Inc.","brandName":"KYBELLA","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2015-","companyName":"Kythera Biopharms","relationship":"Original Developer"},{"period":"present","companyName":"Abbvie","relationship":"Current Owner"}],"publicationCount":3176,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"D11AX24","allCodes":["D11AX24"]},"biosimilarFilings":[],"originalDeveloper":"Kythera Biopharms","recentPublications":[{"date":"2026 Mar 12","pmid":"41905832","title":"Yinchenhao decoction, a compound Chinese herbal medicine, for patients with nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial.","journal":"Journal of integrative medicine"},{"date":"2026 Mar 1","pmid":"41901254","title":"Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.","journal":"Pharmaceuticals (Basel, Switzerland)"},{"date":"2026 Mar 13","pmid":"41898511","title":"Bile Acid Metabolism Affects Muscle Regeneration in Aging Skeletal Muscle in a Manner Associated with Regulation of ABCB1 Expression.","journal":"International journal of molecular sciences"},{"date":"2026 Mar 25","pmid":"41895615","title":"Altered serum 3β-hydroxy bile acids in major depressive disorder and associations with symptom dimensions.","journal":"Journal of affective disorders"},{"date":"2026 Mar 24","pmid":"41880860","title":"Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury.","journal":"EBioMedicine"}],"companionDiagnostics":[],"genericManufacturers":1,"_genericFilersChecked":true,"genericManufacturerList":["Wilshire Pharms Inc"],"status":"approved","companyName":"Abbvie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"2015","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-04-29T00:00:00.000Z","mah":"KYTHERA BIOPHARMS","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:45:50.527817+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}